By incorporating phosphoproteomics, transcriptomics and chemical proteomics data, Winter et al. [75] discovered that the underlying synergy mechanism for the combination of danusertib and bosutinib in the treatment of imatinib-resistant Chronic myelogenous leukemia (CML) might be related with the nonobvious off target effects implicated in the Mitogen-activated protein kinases (MAPK) signaling pathway. Here, WNK2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.